nuc-3373
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2016 (NCT02723240)
Timeline
Indications
Studied for
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Carcinoma, Renal Cell · Phase 1/Phase 2
- Carcinoma, Squamous Cell · Phase 1/Phase 2
- Carcinoma, Transitional Cell · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 2
- Endometrial Neoplasms · Phase 1/Phase 2
- Esophageal Neoplasms · Phase 1/Phase 2
- Hodgkin Disease · Phase 1/Phase 2
- Melanoma · Phase 1/Phase 2
- Mesothelioma · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1/Phase 2
- Stomach Neoplasms · Phase 1/Phase 2
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
Mechanism of action
- Thymidylate synthaseINHIBITOR
TYMS inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C[C@H](NP(=O)(OC[C@H]1O[C@@H](n2cc(F)c(=O)[nH]c2=O)C[C@@H]1O)Oc1cccc2ccccc12)C(=O)OCc1ccccc1- Mol. weight
- 613.54 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2181367 ↗
Also known as
- nuc-3373
- nuc-3373
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05678257 | Phase 2 | Apr 18, 2023 | Nucana |
| NCT05714553 | Phase 1/Phase 2 (Phase 2) | Mar 8, 2023 | Nucana |
| NCT03428958 | Phase 1/Phase 2 (Phase 2) | Oct 16, 2018 | Nucana |
| NCT02723240 | Phase 1 | Jan 1, 2016 | University of Oxford |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Nucana | For profit | 3 | 3 | 1 | 2018 |
| University of Oxford | Academic/Hospital | 1 | 1 | 1 | 2016 |
2 organizations
Page 1 / 1